| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H38N4O3S |
| Molecular Weight | 450.638 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)NC1=CC=CC(=C1)N2CCN(CCCCNS(=O)(=O)CC3CCCCC3)CC2
InChI
InChIKey=SPWZXWDPAWDKQE-UHFFFAOYSA-N
InChI=1S/C23H38N4O3S/c1-20(28)25-22-10-7-11-23(18-22)27-16-14-26(15-17-27)13-6-5-12-24-31(29,30)19-21-8-3-2-4-9-21/h7,10-11,18,21,24H,2-6,8-9,12-17,19H2,1H3,(H,25,28)
| Molecular Formula | C23H38N4O3S |
| Molecular Weight | 450.638 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Naluzotan (PRX-00023), a small molecule, non-azapirone, dual serotonin (5-HT)1A receptor agonist and sigma-1 receptor antagonist, is under development with Proximagen for the treatment of epilepsy. In previous clinical trials, the compound was shown to be safe and well-tolerated in over 400 patients. Epilepsy patients with localisation-related epilepsy have reduced 5-HT1a receptor binding as indicated by positron emission tomography (PET scan). It is thought that by increasing neurotransmitter activity at 5-HT1a receptor sites, seizure incidence and severity may be decreased.
Originator
Approval Year
PubMed
Sample Use Guides
Generalized anxiety disorder: all subjects underwent a 1-week placebo run-in and were randomized to receive once-daily capsules containing either Naluzotan (80 mg/d) or placebo for an additional 8 weeks.
Route of Administration:
Oral
